PRISM BioLab (206A) FY2026 Q1 Earnings Report

Quick View

Executive Summary

FY2026 Q1 results: Revenue ¥1.3B (YoY +5.8%), Operating Loss ¥-2.8B (YoY -20.3%, loss widened), Ordinary Loss ¥-2.7B (YoY -48.3%, loss widened), Net Loss ¥-2.9B (YoY -49.2%, loss widened). While revenue grew modestly, profitability deteriorated significantly across all levels. Gross profit margin of 31.1% indicates product-level profitability is maintained, but selling, general and administrative expenses of ¥3.3B (246.8% of revenue) drove substantial operating losses. Non-operating income of ¥0.2B, primarily from FX gains of ¥0.1B, partially offset losses. An impairment loss of ¥0.2B was recognized as an extraordinary item. The company maintains strong liquidity with cash and deposits of ¥28.2B representing 94.0% of total assets, though accumulated losses of ¥-26.6B continue to erode equity.

Performance Drivers

Revenue increased 5.8% YoY to ¥1.3B, driven by modest top-line growth in core operations. Gross profit of ¥0.4B at a 31.1% margin demonstrates that products and services generate positive unit economics. However, cost of sales of ¥0.9B and significantly elevated SG&A expenses of ¥3.3B created severe operating leverage challenges. The SG&A ratio of 246.8% indicates fixed costs far exceed the current revenue base, representing the primary driver of operating losses.

Operating loss expanded 20.3% YoY to ¥-2.8B, with operating margin at -215.2%. This deterioration was driven by SG&A expenses growing faster than revenue, with insufficient scale to absorb fixed cost structures. The year-over-year increase in SG&A outpaced revenue growth, suggesting cost discipline remains a critical challenge.

Non-operating income of ¥0.2B provided partial offset, consisting mainly of FX gains of ¥0.1B and interest income of ¥0.0B. The non-operating net contribution narrowed the gap between operating and ordinary losses by approximately ¥0.1B. Ordinary loss widened 48.3% to ¥-2.7B.

A non-recurring impairment loss of ¥0.2B was recognized in extraordinary losses, indicating asset revaluation or write-downs of underperforming assets. This one-time charge contributed to net loss expansion but signals potential future relief from depreciation or carrying cost burdens.

Net loss deteriorated 49.2% to ¥-2.9B, with loss per share of ¥-7.74 compared to ¥-5.30 in the prior year. The widening gap between ordinary loss and net loss reflects the impact of extraordinary impairment charges. Income tax expense was minimal at ¥0.0B, consistent with the loss-making position.

This represents a revenue up/profit down pattern, where modest revenue growth failed to translate into profitability improvement due to disproportionate cost structure and one-time charges.

Key Metrics

[Profitability] ROE of -11.7% reflects significant net losses against equity base, deteriorating from cash-backed earnings generation. Operating margin of -215.2% indicates severe operating leverage challenges with SG&A expenses at 246.8% of revenue. Gross profit margin of 31.1% demonstrates product-level profitability is maintained but insufficient scale prevents fixed cost absorption. [Cash Quality] Cash and deposits of ¥28.2B provide exceptionally strong liquidity, with short-term debt coverage ratio of approximately 5.07x against current liabilities of ¥5.6B. Working capital of ¥23.9B reflects substantial liquidity cushion. [Investment Efficiency] Asset turnover of 0.044x indicates low revenue generation relative to asset base, primarily reflecting cash-heavy balance sheet structure. Financial leverage of 1.23x remains conservative. [Financial Health] Equity ratio of 81.2% represents strong capitalization despite accumulated losses. Current ratio of 530.8% indicates extremely robust short-term liquidity position. Debt-to-equity ratio of 0.23x reflects minimal leverage. Retained earnings of ¥-26.6B, deteriorating from ¥-23.8B in prior year, represents ongoing concern requiring earnings recovery to prevent further equity erosion.

Cash Flow Analysis

Cash and deposits of ¥28.2B represent 94.0% of total assets, providing substantial liquidity cushion despite operating losses. The cash position serves as critical buffer against ongoing operating losses of ¥-2.8B per quarter. Current assets of ¥29.5B against current liabilities of ¥5.6B yield a current ratio of 530.8%, indicating no immediate liquidity stress. Contract liabilities of ¥4.2B suggest advance customer payments or deferred revenue, potentially providing working capital support. Total assets decreased from ¥30.9B to ¥30.0B, with the decline primarily reflecting equity erosion from net losses rather than asset disposal. The cash-rich balance sheet structure provides runway to fund operations during the monetization phase, though sustained losses of current magnitude would deplete reserves over multiple periods. Working capital remains robust with no evidence of liquidity stress, though the burn rate implied by quarterly losses of ¥-2.9B would require monitoring if profitability inflection is not achieved.

Earnings Quality

Ordinary loss of ¥-2.7B versus operating loss of ¥-2.8B shows non-operating net contribution of approximately ¥0.1B, consisting primarily of FX gains of ¥0.1B and interest income of ¥0.0B. Non-operating income represents 15.1% of revenue, providing modest offset to operating losses but insufficient to materially improve overall profitability. The extraordinary impairment loss of ¥0.2B represents a non-recurring charge that widened net loss to ¥-2.9B. Excluding this one-time item, recurring losses would approximate ¥-2.7B, still reflecting substantial operating challenges. The quality of earnings is constrained by negative profitability across all levels, with losses driven by structural cost issues rather than revenue deterioration. The absence of operating cash flow data limits assessment of cash conversion, though the cash-backed balance sheet suggests historical cash generation or financing has provided current liquidity reserves. The recurring nature of operating losses and high fixed cost burden indicate earnings quality will remain under pressure until revenue scale improves or cost structure is rationalized.

Shareholder Returns

Annual dividend forecast is ¥0.00 for FY2026, unchanged from prior periods, with no dividend revision this quarter. The company maintains a no-dividend policy consistent with its loss-making position and accumulated deficit of ¥-26.6B. Payout ratio is not applicable given negative earnings. No share buyback activity was disclosed. The absence of shareholder returns reflects management's focus on conserving cash during the monetization phase and prioritizing operational improvement over capital returns. Dividend resumption would require sustained return to profitability and reduction of accumulated losses. The strong cash position of ¥28.2B provides financial capacity for future returns once earnings recovery is achieved, but current financial performance does not support near-term dividend initiation.

Risk Factors

Monetization risk: Revenue of ¥1.3B remains insufficient to cover fixed cost base of ¥3.3B in SG&A expenses, with operating margin of -215.2% indicating business model has not achieved commercial viability at current scale. Continued inability to expand revenue or reduce cost structure would extend losses and accelerate equity erosion.

Accumulated deficit risk: Retained earnings of ¥-26.6B deteriorated by ¥2.9B this quarter, with cumulative losses reducing total equity from ¥27.1B to ¥24.4B. Sustained quarterly losses at current magnitude of ¥-2.9B would deplete equity within 8-9 quarters absent revenue growth or cost reduction, potentially necessitating capital raising.

Asset impairment risk: Recognition of ¥0.2B impairment loss this quarter signals asset quality concerns and potential for additional write-downs. Further impairments would increase non-cash charges and reduce book value, though with limited impact on cash-backed operations given strong liquidity position of ¥28.2B.

Industry Benchmark (Reference - Proprietary Data)

[Industry Position] (Reference - Proprietary Analysis) Given limited historical trend data for the company and absence of specific industry peer comparisons in available data, industry positioning is assessed based on structural characteristics. The company's operating margin of -215.2% and negative ROE of -11.7% indicate pre-commercialization or early-stage growth phase typical of development-stage enterprises. The equity ratio of 81.2% significantly exceeds typical industry norms for mature operating companies, reflecting capital raised in excess of near-term operating needs. This financial structure is more consistent with venture-backed or pre-revenue companies maintaining cash reserves to fund development and commercialization efforts. The absence of debt leverage and reliance on equity financing suggests limited access to or need for traditional bank financing given the loss-making profile. Contract liabilities of ¥4.2B relative to quarterly revenue of ¥1.3B indicate potential milestone or license-based business model common in technology, pharmaceutical, or intellectual property commercialization sectors. The gross margin of 31.1% falls within acceptable ranges for product businesses but requires substantially higher revenue scale to achieve operating leverage.

Key Takeaways from Earnings

Strong liquidity position provides operational runway: Cash and deposits of ¥28.2B representing 94.0% of total assets creates substantial buffer to fund operations during monetization phase, with current quarterly burn rate of approximately ¥-2.9B providing multiple quarters of runway. The current ratio of 530.8% and equity ratio of 81.2% indicate no near-term financial distress despite persistent losses, allowing management time to execute on commercialization strategy without immediate capital constraints.

Cost structure reform is critical priority: SG&A expenses of ¥3.3B representing 246.8% of revenue drive operating losses, with operating margin of -215.2% indicating fundamental misalignment between cost base and revenue scale. The widening of operating losses by 20.3% YoY despite revenue growth of 5.8% demonstrates cost growth is outpacing revenue expansion. Achieving profitability requires either substantial revenue acceleration through successful product commercialization or meaningful fixed cost reduction through operational restructuring. The gross margin of 31.1% confirms product economics are viable, suggesting the path to profitability exists if operating leverage can be achieved.

---

This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Financial Analysis

Executive Summary

FY2026 Q1 results were weak, with a modest revenue increase outweighed by a widening operating loss and a lower non-operating contribution. Revenue rose 5.8% year on year to ¥132 million. Gross profit declined 13.5% to ¥41 million despite the revenue increase. The gross margin contracted by approximately 690 basis points to 31.1% from roughly 38.0% in the prior-year quarter. SG&A expenses increased 14.9% to ¥326 million, materially outpacing revenue growth. Consequently, the operating loss widened 20.3% to ¥284 million. The operating margin deteriorated by approximately 370 basis points to -215.2% from about -188.8%. This is materially below the 5% operating-margin concern threshold and directly addresses the LOW_OPERATING_EFFICIENCY quality alert. Ordinary loss widened 48.3% to ¥267 million, as foreign-exchange gains fell to ¥15 million from ¥55 million in the prior-year period. Net loss widened 49.2% to ¥285 million, equivalent to basic EPS of -¥7.74. The quarterly result also included an impairment loss of ¥18 million, versus ¥10 million a year earlier, which further reduced pre-tax and net income. Cash and deposits remained substantial at ¥2,821 million, representing 94.0% of total assets. Liquidity is therefore strong, with current and quick ratios both at 530.8%. Equity remained high at ¥2,439 million, supporting a low debt-to-equity ratio of 0.23x. However, retained losses expanded to -¥2,662 million, illustrating that the company remains dependent on its capital base and future revenue monetization to absorb ongoing operating losses. Contract liabilities increased to ¥422 million from ¥237 million, which may support future revenue recognition if contractual performance obligations are fulfilled. The key near-term implication is that revenue growth must accelerate materially and/or SG&A growth must normalize for the company to move toward operating leverage and reduce cash burn.

Profitability Analysis

The annualized DuPont ROE was -46.7%, decomposed into a -215.9% net profit margin, 0.176x asset turnover, and 1.23x financial leverage. The principal negative driver is the deeply negative margin rather than financial leverage, as the balance sheet is equity funded and leverage is modest. Asset turnover is also low, reflecting a revenue base of ¥132 million relative to ¥3,002 million of assets, most of which are cash and deposits. Gross margin deterioration to 31.1% from approximately 38.0% reduced the amount of gross profit available to fund research, personnel, and corporate costs. SG&A rose ¥42 million year on year to ¥326 million, compared with a ¥7 million increase in revenue, causing the operating loss to widen by ¥48 million. The operating margin of -215.2% means operating costs substantially exceed the current revenue base; this is the root cause of the LOW_OPERATING_EFFICIENCY alert. For an early-stage drug-discovery company, elevated fixed operating expenditure can be consistent with investment in research and organization building, but its sustainability depends on subsequent licensing, collaboration, milestone, or other revenue expansion. Financial leverage of 1.23x is conservative and is not amplifying losses to a material extent. The tax burden was 1.000 because the loss was largely carried through to net income, while the interest burden of 1.003 indicates no meaningful interest-cost pressure. Foreign-exchange gains of ¥15 million partially offset the operating loss, but were substantially lower than the prior year's ¥55 million, contributing to the sharper ordinary-loss deterioration. The ¥18 million impairment loss is non-recurring in presentation, although repeated impairment charges would weaken the quality and recoverability of the asset base. Margin recovery requires both restoration of gross-margin performance and a substantial improvement in SG&A absorption.

Growth Assessment

Revenue growth of 5.8% to ¥132 million demonstrates some top-line expansion, but the pace was insufficient to cover the 14.9% increase in SG&A. Gross profit fell to ¥41 million because the cost of sales increased 17.5% to ¥92 million, faster than revenue. This indicates that current growth has not translated into operating leverage. The increase in contract liabilities to ¥422 million, up ¥185 million year on year, is a constructive indicator of contracted obligations that may convert into revenue as performance obligations are satisfied. However, the quarterly operating loss of ¥284 million remains more than twice the reported revenue base, so future earnings improvement depends on a much larger scale of commercial or partnership income. The reduction in foreign-exchange gains also shows that ordinary earnings remain sensitive to non-operating items while the core business is loss-making. The increased impairment loss to ¥18 million should be monitored because asset write-downs can indicate a reassessment of expected economic benefits from specific assets. There is no stated earnings forecast in the provided forecast data beyond a zero full-year dividend, so progress against a full-year revenue or earnings target cannot be calculated.

Financial Health

The balance sheet remains liquid and conservatively financed. Current assets of ¥2,953 million exceeded current liabilities of ¥556 million by ¥2,397 million, producing working capital of ¥2,397 million. The current ratio and quick ratio were both 530.8%, far above the 1.0x warning threshold; therefore, there is no evident short-term maturity mismatch. Cash and deposits of ¥2,821 million covered current liabilities by approximately 5.1x. Total liabilities were ¥563 million, equal to 18.8% of total assets, while total equity was ¥2,439 million and the equity ratio was 80.9%. Debt-to-equity of 0.23x is well below the 2.0x aggressive-leverage warning threshold. Noncurrent liabilities were limited to ¥7 million and consisted principally of asset-retirement obligations, indicating limited long-dated balance-sheet obligations. Contract liabilities increased 78.3% year on year to ¥422 million and accounted for about 75% of total liabilities; this reflects obligations to deliver contracted services or other performance obligations rather than conventional interest-bearing financing. Total equity declined by ¥269 million year on year, or 9.9%, primarily reflecting the accumulated quarterly loss. Retained earnings declined to -¥2,662 million from -¥2,376 million, while paid-in capital and capital surplus continued to support positive net assets. The primary financial-health consideration is not debt servicing capacity, but the pace at which recurring operating losses reduce the cash-funded equity cushion.

Notable B/S Changes

Contract liabilities: +¥1.85 billion (+78.3%) to ¥4.22 billion - substantial increase in performance obligations; potential support for future revenue recognition, subject to execution. Total liabilities: +¥1.86 billion (+49.4%) to ¥5.63 billion - driven primarily by higher contract liabilities rather than conventional debt, increasing delivery obligations but not creating significant leverage pressure.

Cash Flow Quality

Cash and deposits declined by ¥94 million year on year to ¥2,821 million, while remaining ample relative to the current operating scale and current liabilities. The quarterly net loss of ¥285 million and the decline in retained earnings demonstrate continuing capital consumption at the earnings level. Contract liabilities increased by ¥185 million year on year, which can provide an operating funding benefit before associated revenue is recognized, subject to delivery of the related obligations. The balance sheet's very high cash weighting limits immediate liquidity stress, but future cash preservation will depend on improving the conversion of contractual activity and research efforts into higher-margin revenue.

Dividend Sustainability

The full-year dividend per share forecast is ¥0. The absence of a planned cash dividend is consistent with the net loss of ¥285 million, negative retained earnings of ¥2,662 million, and the strategic importance of preserving cash for operations. Accordingly, no dividend payout ratio is meaningful while EPS is negative. With ¥2,821 million of cash and deposits, the company has liquidity, but capital retention is more appropriate than shareholder distributions until recurring profitability improves.

Risk Assessment

Business risks include Operating efficiency risk: the -215.2% EBIT margin shows that the present revenue base is far below the level needed to absorb SG&A of ¥326 million per quarter., Revenue-conversion risk: contract liabilities of ¥422 million represent obligations that must be fulfilled before associated revenue can be recognized; delays in delivery or collaboration progress could defer monetization., Pharmaceutical development and commercialization risk: drug-discovery businesses face clinical, regulatory, partner-execution, and intellectual-property risks that can delay or reduce economic returns from research programs., Margin risk: gross margin fell by approximately 690 basis points year on year to 31.1%, and a sustained higher cost-of-sales ratio would increase the revenue scale needed to reach break-even., Foreign-exchange sensitivity: FX gains fell from ¥55 million to ¥15 million year on year, demonstrating that non-operating results can meaningfully affect ordinary income while core operations remain loss-making..

Financial risks include Cash-consumption risk: the ¥285 million quarterly net loss reduced equity and retained earnings, and persistent losses would progressively diminish the substantial current cash balance., Impairment risk: impairment loss increased to ¥18 million from ¥10 million, requiring continued attention to the recoverability of recognized assets., Capital-raising risk: although debt leverage is low and liquidity is strong, sustained operating losses may ultimately require external capital if revenue monetization does not scale..

Key concerns include LOW_OPERATING_EFFICIENCY is the most material quality alert: EBIT margin of -215.2% is driven by SG&A growing 14.9% while revenue grew only 5.8%, creating a widening operating loss., The ¥48 million year-on-year deterioration in operating loss indicates that current cost growth is not yet supported by sufficient revenue expansion., The ¥269 million year-on-year reduction in equity lowers the capital cushion, despite the still-high 80.9% equity ratio., The investment case is highly dependent on evidence that contract liabilities convert to revenue and that revenue growth can exceed the fixed-cost base..

Investment Implications

Key takeaways include Q1 revenue growth was positive at 5.8%, but gross profit declined and operating losses widened., Gross margin fell to 31.1%, while SG&A reached ¥326 million, resulting in a -215.2% operating margin., Liquidity is a major balance-sheet strength, with ¥2,821 million of cash, a 530.8% current ratio, and only 0.23x debt-to-equity., Contract liabilities increased to ¥422 million, providing a potentially constructive indicator for future revenue conversion., No dividend is planned for the full year, preserving capital while the company remains loss-making..

Metrics to watch include Revenue growth and the conversion of ¥422 million of contract liabilities into recognized revenue, Gross margin recovery from 31.1%, SG&A growth relative to revenue growth, Quarterly operating-loss trajectory and annualized ROE, Cash and deposits relative to recurring operating losses, Further impairment charges and the recoverability of relevant assets, Foreign-exchange gains or losses affecting ordinary income.

Regarding relative positioning, The company is financially conservative relative to highly leveraged issuers, supported by an 80.9% equity ratio, 0.23x debt-to-equity, and a cash-dominant asset base. Operationally, however, it remains materially below mature profitable pharmaceutical-sector profitability benchmarks because the current revenue base does not cover its operating-cost structure.